Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | HPN | P05981 | 4/20 | 0.35 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.35 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5005231 | 1.00 | F2 (0.36) | F2PRSS1PLAUMMP9HPN | |
| SCHEMBL5002042 | 1.00 | F2 (0.36) | F2PRSS1PLAUMMP9HPN | |
| SCHEMBL5002010 | 0.94 | MMP9 (0.41) | F2PRSS1PLAUMMP9KDM4C | |
| SCHEMBL4331450 | 0.94 | MMP9 (0.41) | F2PRSS1PLAUMMP9KDM4C | |
| SCHEMBL5002169 | 0.89 | F2 (0.38) | F2PRSS1PLAUMMP9HPN | |
| SCHEMBL5002161 | 0.89 | F2 (0.38) | F2PRSS1PLAUMMP9HPN | |
| SCHEMBL5001776 | 0.89 | TDP1 (0.42) | F2PRSS1PLAUMMP9HPN | |
| SCHEMBL5001825 | 0.89 | TDP1 (0.42) | F2PRSS1PLAUMMP9HPN | |
| SCHEMBL5001746 | 0.89 | TDP1 (0.42) | F2PRSS1PLAUMMP9HPN | |
| SCHEMBL5007662 | 0.87 | KDM4E (0.38) | F2PRSS1PLAUMMP9HPN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | BDKRB1, BDKRB2, FPR1 | F2 541/4885PRSS1 526/4885PLAU 1322/4885 |
| US-20060100216-A1 | Novel B1 bradykinin receptor antagonists | BDKRB1, BDKRB2, EDNRB | F2 298/4885PRSS1 345/4885PLAU 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.